셀트리온, ADC 후보물질 환자 투약 시작…신약 밸류에이션 극대화

Celltrion is accelerating its transition from a biosimilar leader to a novel drug developer by advancing its ADC and multi-antibody candidates into human clinical trials. The strategic use of FDA Fast Track designations for these oncology assets aims to minimize development timelines and maximize the company's long-term valuation in the high-growth biologics market.